
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
TH | Toronto | CAD | Real-time | |
THTX | NASDAQ | USD | Real-time | |
TH | CBOE Canada | CAD | Real-time |
Theratechnologies Inc., a biopharmaceutical company, focuses on the commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its product pipeline includes tesamorelin F8 in HIV-associated lipodystrophy that is in Phase 2 clinical trials for the treatment of nonalcoholic steatohepatitis; SORT1+ Technology that is in Phase 1 clinical trials for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; sudocetaxel zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company also commercializes olezarsen, an RNA-targeted medicine for the treatment of familial chylomicronemia syndrome and severe hypertriglyceridemia; and donidalorsen, an RNA-targeted medicine that targets the acute attacks of hereditary angioedema. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Name | Age | Since | Title |
---|---|---|---|
George R. Merriam | - | - | Member of the Scientific Advisory Board |
Roger Guillemin | - | - | Member of the Scientific Advisory Board |
Steven Grinspoon | - | - | Member of the Scientific Advisory Board |
Peter Reiss | - | - | Member of the Scientific Advisory Board |
David Clemmons | - | - | Member of the Scientific Advisory Board |
Julian Falutz | - | - | Member of the Scientific Advisory Board |
Paul Lévesque | 61 | 2020 | President, CEO & Director |
Dawn A. Svoronos | 72 | 2013 | Independent Director |
Andrew T. Molson | 57 | 2020 | Independent Director |
Frank A. Holler | 68 | 2021 | Independent Chairman |
Dale MacCandlish-Weil | 69 | 2017 | Independent Director |
Jordan Zwick | 37 | 2024 | Independent Director |
Joseph P. Arena | 69 | 2021 | Independent Director |
Elina Tea | 48 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review